Abstract
Customized chemotherapy is increasingly used in the management of patients with advanced non-small cell lung cancer (NSCLC). However, the most reliable methodology to determine biomarker status is neither fully elucidated nor agreed upon. Accordingly, we evaluated the predictive efficiency of qRT-PCR and immunohistochemical analysis (IHC) on excision cross complementation group 1 (ERCC1), breast cancer susceptibility gene 1 (BRCA1), ribonucleotide reductase subunit M1 (RRM1) and class III ß-tubulin (TUBB3).
Original language | English |
---|---|
Journal | Lung Cancer |
Volume | 75 |
Issue number | 3 |
Pages (from-to) | 306-12 |
Number of pages | 7 |
ISSN | 0169-5002 |
DOIs | |
Publication status | Published - 2012 |